The Filing Desk

Evommune vs Prelude Therapeutics

Evommune EVMN · Prelude Therapeutics PRLD · Pharmaceuticals

Evommune reported revenue of $13 million in fiscal 2025, about the same as Prelude Therapeutics' $12 million in fiscal 2025. Evommune's revenue grew 85.7% in its latest year, and Prelude Therapeutics' grew 73.4%. Evommune had an operating margin of -623.6%, against -861.3% at Prelude Therapeutics. Free cash flow was −$77 million at Evommune and −$56 million at Prelude Therapeutics.

Side by side

EvommunePrelude Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$13M$12M
Revenue growth85.7%73.4%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−623.6%−861.3%
Net margin−529.8%−819.6%
Free cash flow−$77M−$56M
Free cash flow margin−589.8%−464.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count306.9%1.5%
Last close$7.24$3.25
P/E at the last close——
Insider trades, last 12 monthsbought $163,610, sold $2.3 millionbought $12.5 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
EvommunePrelude Therapeutics
Operating margin
Percent of revenue
EvommunePrelude Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvommunePrelude Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Evommune and Prelude Therapeutics pages.